DNA and RNA Delivery Methods for Gene Therapy Compared

What is the mechanistic difference between DNA and RNA delivery in gene therapy?
DNA-based gene therapy requires the payload to reach the nucleus, where it serves as a transcriptional template for the host cell machinery. For plasmid DNA, nuclear entry depends primarily on mitotic breakdown of the nuclear envelope, limiting efficiency in post-mitotic or slowly dividing cells. RNA-based approaches bypass transcription entirely, acting directly in the cytosol. This distinction determines not only the delivery platform required but also expression kinetics, durability, and the intracellular barriers that must be overcome.

Why does AAV persist in post-mitotic cells but lose efficacy in dividing tissues?
Recombinant AAV vectors persist primarily as extrachromosomal episomes rather than integrating into the host genome. In post-mitotic cells such as neurons and hepatocytes, episomal DNA is stable and can support long-term transgene expression. In dividing cells, episomal genomes are not replicated and are progressively diluted with each round of cell division, leading to gradual loss of expression. This makes AAV well suited to non-dividing tissues but a poor choice for applications where the target cell population turns over, such as hematopoietic stem cell modification.

Why does AAV administration generate neutralizing antibodies that prevent redosing, and what strategies are being explored to address this?
Following AAV transduction, capsid proteins are processed through the MHC class I and II antigen presentation pathway, triggering B cell activation and the production of anti-AAV IgG neutralizing antibodies. These antibodies persist long-term and block vector transduction upon re-exposure to the same serotype. Strategies under investigation include capsid engineering to evade existing antibodies, serotype switching, transient immunosuppression prior to redosing, plasmapheresis to deplete circulating antibodies, and IgG-degrading enzymes such as imlifidase. Each approach involves trade-offs in immune burden, manufacturing complexity, and regulatory precedent.

What determines endosomal escape efficiency in LNP-mediated RNA delivery, and why does it remain a bottleneck?
Endosomal escape in LNPs is driven primarily by the ionizable lipid component, which becomes protonated in the acidic endosomal environment and promotes membrane destabilization through formation of non-bilayer lipid structures. However, the efficiency of this process is estimated to be low, with most studies suggesting that only a small fraction of endocytosed LNPs successfully release their cargo into the cytosol. The remainder are trafficked to lysosomes and degraded. Endosomal escape efficiency is sensitive to lipid pKa, LNP composition, particle size, and the rate of endosomal acidification in the target cell type, making it a formulation-dependent variable rather than a solved problem.

What are the CMC implications of switching between RNA payload types within the same LNP platform?
LNP formulations are optimized for specific payload characteristics including molecular weight, secondary structure, and charge density. Switching between payload types, for example from siRNA to mRNA or from mRNA to self-amplifying RNA, requires reassessment of encapsulation efficiency, particle size distribution, polydispersity, and potency. Changes in payload length and structure can alter ionizable lipid to RNA ratios, affect endosomal escape behavior, and shift immunogenicity profiles. Regulatory agencies expect bridging data demonstrating comparability when payload type changes within a platform, and analytical methods validated for one RNA class may not be directly transferable to another.

Why is lentiviral vector manufacturing classified as very high CMC complexity relative to other gene therapy platforms?
Lentiviral vector manufacturing involves transient transfection of producer cells with multiple plasmid components, virus-like particle harvest, and extensive downstream purification to remove process-related impurities including residual plasmid DNA, helper proteins, and empty particles. Lot-to-lot consistency is challenging due to the biological variability of transient production systems. Potency assays must capture both transduction efficiency and integration competence. Long-term follow-up for integration site analysis adds post-manufacturing obligations. Regulatory expectations for comparability, identity, purity, and safety testing are among the most demanding of any gene therapy modality.

What distinguishes GalNAc conjugate pharmacology from LNP-mediated siRNA delivery to the liver?
GalNAc conjugates exploit the asialoglycoprotein receptor (ASGPR), which is highly expressed on hepatocytes and mediates rapid, receptor-dependent endocytosis following subcutaneous administration. After endosomal release, the naked oligonucleotide engages RISC or RNase H depending on the mechanism of action. The result is highly predictable hepatocyte targeting, low formulation complexity, and durable pharmacodynamic effects that enable quarterly or biannual dosing for some approved agents. LNP-mediated siRNA delivery achieves hepatic accumulation primarily through ApoE-mediated uptake following intravenous administration, requires formulation of the oligonucleotide within a particle, and involves endosomal escape as a rate-limiting step. GalNAc conjugates are not a general RNA delivery platform and are unsuitable for large transcripts or extrahepatic targets.

Can lipid nanoparticles deliver plasmid DNA, and what are the key differences from RNA delivery?
LNPs can encapsulate and deliver plasmid DNA, and this application has been explored in research and early clinical settings. However, DNA delivery via LNP introduces an additional intracellular barrier not present for RNA: after endosomal escape, plasmid DNA must cross the nuclear envelope to be transcribed. In non-dividing cells, this requires active nuclear import, which is inefficient for large constructs. Expression onset is also more variable than for mRNA, reflecting the cell-cycle dependence of nuclear entry. As a result, LNP-mediated DNA delivery is substantially less efficient than RNA delivery in most contexts, and RNA represents the more clinically advanced application of the platform.

What are the main analytical challenges in characterizing non-viral RNA delivery systems compared to viral vectors?
Non-viral RNA delivery systems such as LNPs present distinct analytical challenges including measurement of encapsulation efficiency, particle size distribution, polydispersity, surface charge, lipid composition, and RNA integrity simultaneously. Endosomal escape cannot be directly measured in standard release assays and is inferred from potency readouts. For targeted LNPs carrying surface ligands, ligand density, orientation, and binding affinity add further characterization requirements. Viral vectors by contrast have defined capsid structures amenable to established identity and purity assays, though potency and immunogenicity characterization remain complex. The absence of pharmacopoeial standards for LNP characterization means that analytical strategies are largely platform-specific and subject to regulatory negotiation.

Why cannot AAV package RNA?
AAV packaging is dependent on specific DNA recognition sequences called inverted terminal repeats (ITRs), which are located at both ends of the vector genome and are essential for encapsidation by the AAV capsid. RNA lacks ITR sequences and is not recognized by the packaging machinery. RNA is also insufficiently stable under the conditions of AAV production, which involves high temperatures, organic solvents, and density gradient centrifugation steps that would degrade RNA before packaging could occur. These are fundamental biological and biochemical constraints, not engineering limitations that can currently be overcome.

Why does AAV administration prevent redosing with the same serotype?
Following AAV transduction, capsid proteins are processed through the MHC class I and II antigen presentation pathway, triggering B cell activation and sustained production of anti-AAV IgG neutralizing antibodies. These antibodies persist long-term and block vector transduction upon re-exposure to the same serotype, effectively precluding redosing in most systemic indications.

How prevalent is pre-existing AAV seropositivity and what are the clinical implications?
Pre-existing neutralizing antibody seroprevalence ranges from 40% to 70% depending on serotype and geographic region, reflecting widespread prior exposure to wild-type AAV. Seropositive patients are excluded from most systemic AAV trials, as even low-titer neutralizing antibodies can significantly reduce transduction efficiency. This exclusion meaningfully constrains the eligible patient population and complicates patient stratification at the clinical trial design stage.